- Home
- NBBK vs CSTL Comparison
NBBK vs CSTL Comparison
Compare NBBK & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- CSTL
- Stock Information
- Founded
- NBBK 1892
- CSTL 2007
- Country
- NBBK United States
- CSTL United States
- Employees
- NBBK N/A
- CSTL N/A
- Industry
- NBBK
- CSTL Medical Specialities
- Sector
- NBBK
- CSTL Health Care
- Exchange
- NBBK Nasdaq
- CSTL Nasdaq
- Market Cap
- NBBK 666.6M
- CSTL 568.2M
- IPO Year
- NBBK N/A
- CSTL 2019
- Fundamental
- Price
- NBBK $17.25
- CSTL $21.27
- Analyst Decision
- NBBK Buy
- CSTL Strong Buy
- Analyst Count
- NBBK 1
- CSTL 6
- Target Price
- NBBK $22.00
- CSTL $40.00
- AVG Volume (30 Days)
- NBBK 239.2K
- CSTL 341.5K
- Earning Date
- NBBK 04-22-2025
- CSTL 05-05-2025
- Dividend Yield
- NBBK N/A
- CSTL N/A
- EPS Growth
- NBBK 421.39
- CSTL N/A
- EPS
- NBBK 1.18
- CSTL 0.62
- Revenue
- NBBK $169,131,000.00
- CSTL $332,069,000.00
- Revenue This Year
- NBBK N/A
- CSTL N/A
- Revenue Next Year
- NBBK N/A
- CSTL $3.34
- P/E Ratio
- NBBK $14.12
- CSTL $35.40
- Revenue Growth
- NBBK 25.80
- CSTL 51.09
- 52 Week Low
- NBBK $13.64
- CSTL $16.97
- 52 Week High
- NBBK $21.05
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- NBBK 51.40
- CSTL 53.28
- Support Level
- NBBK $16.09
- CSTL $21.06
- Resistance Level
- NBBK $16.56
- CSTL $21.81
- Average True Range (ATR)
- NBBK 0.79
- CSTL 1.29
- MACD
- NBBK 0.11
- CSTL 0.38
- Stochastic Oscillator
- NBBK 81.48
- CSTL 70.99
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.